|
C11ORF58 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.16980000020028E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.39089999998221E-06 |
| Normal-vs-Stage2 |
1.581940E-04 |
| Normal-vs-Stage3 |
8.02389999998709E-07 |
| Normal-vs-Stage4 |
3.08239989088577E-10 |
| Stage1-vs-Stage2 |
6.032600E-01 |
| Stage1-vs-Stage3 |
1.412960E-01 |
| Stage1-vs-Stage4 |
1.116380E-03 |
| Stage2-vs-Stage3 |
6.260400E-01 |
| Stage2-vs-Stage4 |
8.074000E-02 |
| Stage3-vs-Stage4 |
1.127220E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.18609999996988E-08 |
| Normal-vs-AfricanAmerican |
4.510100E-02 |
| Normal-vs-Asian |
1.3879000000383E-06 |
| Caucasian-vs-AfricanAmerican |
1.407200E-01 |
| Caucasian-vs-Asian |
7.295400E-01 |
| AfricanAmerican-vs-Asian |
1.736350E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.26919999954289E-07 |
| Normal-vs-Female |
6.05240000006724E-07 |
| Male-vs-Female |
2.742000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.4857999999981E-05 |
| Normal-vs-Age(41-60Yrs) |
4.54110000047692E-07 |
| Normal-vs-Age(61-80Yrs) |
5.72789999875312E-08 |
| Normal-vs-Age(81-100Yrs) |
3.716400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.184400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.135900E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.731400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.043600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.215800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.115000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.984200E-02 |
| Classical-VS-Follicular |
3.467600E-01 |
| Classical-VS-Other |
5.335400E-01 |
| Classical-VS-Normal |
2.01349999995326E-06 |
| Tall-VS-Follicular |
3.708800E-01 |
| Tall-VS-Other |
7.756000E-01 |
| Tall-VS-Normal |
2.42829999996808E-06 |
| Follicular-VS-Other |
8.606200E-01 |
| Follicular-VS-Normal |
2.40619999999359E-05 |
| Other-VS-Normal |
1.665530E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.6869999996949E-07 |
| Normal-vs-N1 |
8.10139999529724E-08 |
| N0-vs-N1 |
1.696380E-01 |
|
|
